Presentation and Management of Docetaxel-related Adverse Effects in Patients with Breast Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2014 Jun 7

PMID 24904223

Citations 79

Authors

Maria Y Ho

John R Mackey

Affiliations

Soon will be listed here.

Abstract

The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic setting. Although well tolerated by the majority of patients, docetaxel toxicity may limit the dose which can be administered. Adverse events include infusion reactions, febrile neutropenia, fatigue, fluid retention, pneumonitis, cutaneous and nail toxicity, epiphora and lacrimal duct stenosis, gastrointestinal complications, and neuropathies. In this review, we explore these complications and how they can be effectively managed to improve patient quality of life during and following docetaxel therapy.

Citing Articles

Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines.

Penata-Taborda A, Espitia-Perez P, Espitia-Perez L, Coneo-Pretelt A, Brango H, Ricardo-Caldera D Int J Mol Sci. 2025; 26(3).

PMID: 39940782 PMC: 11817897. DOI: 10.3390/ijms26031013.

Quality of Life and Symptom Burden in Non-Small-Cell Lung Cancer Patients Receiving Second-Line Chemotherapy Compared with Immunotherapy.

Stylianou C, Kalemikerakis I, Konstantinidis T, Kafazi A, Alevizopoulos N, Parissopoulos S Medicina (Kaunas). 2024; 60(11).

PMID: 39597030 PMC: 11596781. DOI: 10.3390/medicina60111845.

Role of scaffold proteins in the heterogeneity of glioblastoma.

Iyer V, Donahue J, Osman M Cell Commun Signal. 2024; 22(1):477.

PMID: 39375741 PMC: 11457365. DOI: 10.1186/s12964-024-01809-1.

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study.

Low K, Foulkes P, Hills F, Roberts H, Stordal B Cancer Med. 2024; 13(18):e70248.

PMID: 39315544 PMC: 11420655. DOI: 10.1002/cam4.70248.

CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.

Yuan X, Hao X, Chan H, Zhao N, Pedroza D, Liu F JCI Insight. 2024; 9(20).

PMID: 39287984 PMC: 11533985. DOI: 10.1172/jci.insight.182621.

References

Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson B . Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 2006; 24(31):4963-70. DOI: 10.1200/JCO.2005.05.0294. View

Semb K, Aamdal S, Oian P . Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998; 16(10):3426-32. DOI: 10.1200/JCO.1998.16.10.3426. View

Verma S, Maraninchi D, OShaughnessy J, Jamieson C, Jones S, Martin M . Capecitabine plus docetaxel combination therapy. Cancer. 2005; 103(12):2455-65. DOI: 10.1002/cncr.21122. View

Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A . Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011; 29(29):3877-84. DOI: 10.1200/JCO.2010.28.5437. View

Heys S, Hutcheon A, Sarkar T, Ogston K, Miller I, Payne S . Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002; 3 Suppl 2:S69-74. DOI: 10.3816/cbc.2002.s.015. View

Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A . Coping with toxicities of docetaxel (Taxotere). Ann Oncol. 1993; 4(7):610-1. DOI: 10.1093/oxfordjournals.annonc.a058599. View

Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T . Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358(16):1663-71. PMC: 2743943. DOI: 10.1056/NEJMoa0707056. View

Jones S, Holmes F, OShaughnessy J, Blum J, Vukelja S, McIntyre K . Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009; 27(8):1177-83. DOI: 10.1200/JCO.2008.18.4028. View

Monga U, Garber S, Thornby J, Vallbona C, Kerrigan A, Monga T . Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil. 2007; 88(11):1416-22. DOI: 10.1016/j.apmr.2007.08.110. View

10.

Piccart M, KLIJN J, Paridaens R, Nooij M, Mauriac L, Coleman R . Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997; 15(9):3149-55. DOI: 10.1200/JCO.1997.15.9.3149. View

11.

Ochoa R, Bejarano P, Gluck S, Montero A . Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep. 2012; 6:413. PMC: 3533898. DOI: 10.1186/1752-1947-6-413. View

12.

Chan A, Su C, De Boer R, Gajdatsy A . Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol. 2013; 31(17):2123-7. DOI: 10.1200/JCO.2012.45.6574. View

13.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels J, Penault-Llorca F . Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist. 2012; 17(7):900-9. PMC: 3399644. DOI: 10.1634/theoncologist.2011-0442. View

14.

Stemmler H, Harbeck N, Groll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W . Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer. Oncology. 2011; 79(3-4):197-203. DOI: 10.1159/000320640. View

15.

Can G, Aydiner A, Cavdar I . Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs. 2011; 16(3):270-5. DOI: 10.1016/j.ejon.2011.06.007. View

16.

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

17.

Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J, Weaver C . Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352(22):2302-13. DOI: 10.1056/NEJMoa043681. View

18.

Wilcken N, Hornbuckle J, Ghersi D . Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003; (2):CD002747. PMC: 8094405. DOI: 10.1002/14651858.CD002747. View

19.

Valero V, Forbes J, Pegram M, Pienkowski T, Eiermann W, von Minckwitz G . Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active.... J Clin Oncol. 2010; 29(2):149-56. DOI: 10.1200/JCO.2010.28.6450. View

20.

Chew L, Chuen V . Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract. 2008; 15(1):29-34. DOI: 10.1177/1078155208096111. View